AOD-9604 vs Tirzepatide
A side-by-side research comparison of AOD-9604 and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AOD-9604 | Tirzepatide |
|---|---|---|
| Full name | Advanced Obesity Drug Fragment 176-191 (Modified) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | FDA Approved |
| Mechanism | Mimics the lipolytic domain of growth hormone (hGH 176-191), stimulating fat oxidation and inhibiting de novo lipogenesis through pathways independent of IGF-1 and growth signaling. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 1815.08 Da | 4,814 Da |
| Half-life | ~2-3 hours | 5 days (120 hours) |
| Bioavailability | ~90% subcutaneous | High (SubQ ~80%) |
| Typical dose | 300 mcg | 2.5 mg → titrate up to 15 mg |
| Frequency | Daily (morning, fasted) | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
AOD-9604 reported benefits
- Fat loss without muscle wasting
- No effect on blood sugar
- Cartilage repair properties
- No HGH-related side effects
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.